Epigenetic reprogramming synergizes with PD-1/PD-L1 inhibition for cell-targeted therapy in hepatocellular carcinoma

被引：0
|
作者：
Sukowati, Caecilia [1 ,2 ,3 ]
Cabral, Loraine Kay [3 ,4 ]
Anfuso, Beatrice [5 ]
Tiribelli, Claudio [3 ]
机构：
[1] Natl Res & Innovat Agcy Indonesia, Jakarta, Indonesia
[2] Eijkman Res Ctr Mol Biol, Jakarta, Indonesia
[3] Fdn Italiana Fegato ONLUS, Basovizza, Italy
[4] Univ Trieste, Doctoral Sch Mol Biomed, Trieste, Italy
[5] Univ Trieste, Dept Life Sci, Trieste, Italy
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-273
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [21] PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
    Joseph, Richard W.
    Millis, Sherri Z.
    Carballido, Estrella M.
    Bryant, David
    Gatalica, Zoran
    Reddy, Sandeep
    Bryce, Alan H.
    Vogelzang, Nicholas J.
    Stanton, Melissa L.
    Castle, Erik P.
    Ho, Thai H.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1303 - 1307
  • [22] Structural basis of PD-1/PD-L1 checkpoint inhibition
    Magiera, K.
    Zak, K.
    Berlicki, L.
    Domling, A.
    Holak, T.
    Dubin, G.
    FEBS JOURNAL, 2017, 284 : 45 - 45
  • [23] Miniprotein engineering for inhibition of PD-1/PD-L1 interaction
    Ciesiolkiewicz, Agnieszka
    Perez, Juan Lizandra
    Skalniak, Lukasz
    Nocen, Pawel
    Berlicki, Lukasz
    PROTEIN SCIENCE, 2024, 33 (08)
  • [24] Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
    Chen, Xi
    Pan, Xiaohui
    Zhang, Wenxin
    Guo, Hongjie
    Cheng, Shuyuan
    He, Qiaojun
    Yang, Bo
    Ding, Ling
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (05) : 723 - 733
  • [25] Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
    Xi Chen
    Xiaohui Pan
    Wenxin Zhang
    Hongjie Guo
    Shuyuan Cheng
    Qiaojun He
    Bo Yang
    Ling Ding
    ActaPharmaceuticaSinicaB, 2020, 10 (05) : 723 - 733
  • [26] Targeting the PD-1/PD-L1 interaction in nasopharyngeal carcinoma
    Johnson, David
    Ma, Brigette B. Y.
    ORAL ONCOLOGY, 2021, 113
  • [27] Combination of PD-1/PD-L1 checkpoint blockade and dendritic cell therapy
    Nesselhut, J.
    Marx, D.
    Lange, H.
    Chang, R. Y.
    Nesselhut, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 : 95 - 95
  • [28] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
    Jilkova, Zuzana Macek
    Aspord, Caroline
    Decaens, Thomas
    CANCERS, 2019, 11 (10)
  • [29] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [30] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
12345